Skip to main content
MESOBLAST LTD logo

MESOBLAST LTD — Investor Relations & Filings

Ticker · MESO ISIN · US5907171046 ASX Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2021-12-13 Regulatory Filings
Country US United States of America
Listing ASX MESO

About MESOBLAST LTD

https://www.mesoblast.com/

Mesoblast is a regenerative medicine company that develops allogeneic (off-the-shelf) cellular medicines for severe and life-threatening inflammatory conditions. The company utilizes its proprietary mesenchymal lineage cell (MSC) technology platform to create treatments for inflammatory ailments, cardiovascular disease, and chronic back pain. The technology sources rare MSCs from the bone marrow of healthy adult donors, which are then expanded using proprietary processes for industrial-scale manufacturing. A key feature of these cells is their ability to be administered without donor-recipient matching or immune suppression. The therapeutic candidates are designed to respond to tissue damage by secreting mediators that promote tissue repair and modulate immune responses. The company's late-stage portfolio includes remestemcel-L for acute graft versus host disease (GVHD) and acute respiratory distress syndrome (ARDS), REVASCOR® for advanced chronic heart failure, and MPC-06-ID for chronic low back pain.

Recent filings

Filing Released Lang Actions
Update on Novartis Agreement 2 pages 136.9KB
Regulatory Filings Classification · 95% confidence The document is a press release announcing the termination of an agreement between Mesoblast and Novartis, along with a description of Mesoblast's business focus and forward-looking statements. It does not contain financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. There is no indication of a shareholder meeting, voting results, or management changes. The content is primarily an update on a business agreement and future plans, typical of a general regulatory announcement or corporate news release. The document length is 6814 characters, which is sufficient for a detailed announcement but lacks the structure and content of a formal financial or regulatory report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other categories.
2021-12-13 English
6-K
Regulatory Filings
2021-12-07 English
Global CardioVascular Clinical Trialists Forum Presentation 17 pages 1.7MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation of clinical trial results (DREAM HF Trial) for a treatment related to heart failure, including study design, endpoints, statistical analyses, and conclusions. It is structured as a presentation with slides, including forward-looking statements, trial overview, clinical endpoints, and key next steps. The content is focused on scientific and clinical data rather than financial statements or regulatory filings. The presence of detailed trial data, Kaplan-Meier analyses, and clinical endpoints strongly indicates this is an investor or scientific presentation rather than a formal regulatory report or earnings release. There is no indication that this is an Annual Report, Earnings Release, or Regulatory Filing. The document is not a transcript of a call, nor a voting result or management change announcement. It is a presentation aimed at investors or stakeholders to communicate clinical trial results and company strategy. Therefore, the most appropriate classification is Investor Presentation (IP). The document length (over 14,000 characters) and detailed content support this classification with high confidence.
2021-12-05 English
Rexlemestrocel Greatest Benefit in Diabetics and Ischemics 3 pages 236.0KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement of clinical trial results from the DREAM-HF Phase 3 trial regarding the treatment benefit of rexlemestrocel-L in high-risk heart failure patients. It discusses FDA guidance, clinical endpoints, and plans to submit data for regulatory approval. The content focuses on clinical trial outcomes, regulatory interactions, and forward-looking statements about potential FDA approval pathways. It does not contain financial statements, earnings data, or detailed management analysis of financial results. It is not a transcript of a call, nor a report on board changes, capital updates, or legal proceedings. The document is a press release announcing clinical trial results and regulatory update rather than a formal regulatory filing or financial report. Given the nature of the content and the absence of financial data or formal report structure, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory announcements and compliance-related disclosures that do not fit other categories.
2021-12-05 English
6-K
Regulatory Filings
2021-12-02 English
Mesoblast Chairman Message to 2021 AGM 3 pages 216.4KB
AGM Information Classification · 95% confidence The document is titled 'CHAIRMAN’S ADDRESS TO SHAREHOLDERS 2021 MESOBLAST ANNUAL GENERAL MEETING' and contains a detailed address from the chairman discussing the company's progress, regulatory updates, board composition, and future outlook. It references the Annual General Meeting (AGM) context and includes forward-looking statements typical of such shareholder addresses. There are no detailed financial statements or comprehensive financial performance data that would classify it as an Annual Report (10-K) or Interim Report (IR). It is not a transcript of a call, nor an announcement of voting results or capital changes. The content is consistent with materials shared during an AGM, specifically a chairman's address to shareholders at the AGM. The document length (10,706 characters) supports it being a full address rather than a brief announcement. Therefore, the most appropriate classification is AGM Information (AGM-R).
2021-11-28 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.